Hyperthermic Intraperitoneal Treatment of rmhTNF for CRCPM: Phase II Clinical Trial

Inclusion Criteria: * Adenocarcinoma of colonic and peritoneal reflexive superior rectum was confirmed by pathology, aged 18-70 years; * Body condition score (PS) 0 \~ 1 in the Eastern Tumor Collaboration Group (ECOG); * Preoperative clinical stage was M1c; * No neoadjuvant therapy was performed; * Histopathologically confirmed as peritoneal metastases of colorectal cancer \> 10cm from the anus, R0-resected, adenocarcinoma/mucinous adenocarcinoma * The functions of vital organs shall meet the following requirements; * Be able to understand the situation of this study and sign informed consent. Exclusion Criteria: * Allergic history of TNF and its derivatives; * Patients with fever (\>38℃); * Active hepatitis and peripheral neuropathy (e.g., peripheral neuritis, pseudomeningitis, motor neuritis, and sensory disorders); * Pregnant or lactating women, or potentially pregnant women and sexually active men who refuse/cannot receive medically acceptable forms of contraception; * Patients with a history of malignant tumor; * Clinical symptoms or diseases of the heart that are not well controlled. * Subject has any active autoimmune disease or history of autoimmune disease (such as the following, but not limited to: interstitial pneumonia, uveitis, enteritis, hepatitis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism; * The subject has a known history of psychotropic substance abuse, alcoholism or drug use; Subjects innate or acquired immune function defects (such as HIV infection), or active hepatitis * Other conditions in which the investigator thinks the patient should not participate in the study; * A history of neurological or psychiatric disorders, such as major depression or dementia, that may affect the informed study or follow-up evaluation;